for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Pfizer Inc.

PFE.N

Latest Trade

40.79USD

Change

1.38(+3.50%)

Volume

7,661,230

Today's Range

40.31

 - 

41.41

52 Week Range

27.89

 - 

41.99

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
39.41
Open
40.49
Volume
7,661,230
3M AVG Volume
689.42
Today's High
41.41
Today's Low
40.31
52 Week High
41.99
52 Week Low
27.89
Shares Out (MIL)
5,559.96
Market Cap (MIL)
213,002.20
Forward P/E
13.64
Dividend (Yield %)
3.97

Next Event

Q4 2020 Pfizer Inc Earnings Release

Latest Developments

更多

UK Authorizes Pfizer-Biontech COVID-19 Vaccine

Pfizer Says Co & Biontech Achieve First Authorization In World For A Vaccine To Combat Covid-19

Biontech And Pfizer Achieve Authorization For COVID-19 Vaccine

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Pfizer Inc.

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

Industry

Biotechnology & Drugs

Contact Info

235 E 42ND ST

NEW YORK, NY

10017-5703

United States

+1.212.5732323

https://www.pfizer.com/

Executive Leadership

Albert Bourla

Chairman of the Board, Chief Executive Officer

John D. Young

Chief Business Officer, Group President

Frank A. D'Amelio

Chief Financial Officer, Executive Vice President - Business Operations and Global Supply

Angela Hwang

Group President, Pfizer Biopharmaceuticals Group

Dawn Rogers

Chief Human Resource Officer, Executive Vice President

Key Stats

2.62 mean rating - 21 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

52.5K

2018

53.6K

2019

51.8K

2020(E)

48.5K
EPS (USD)

2017

2.650

2018

3.000

2019

2.950

2020(E)

2.867
Price To Earnings (TTM)
25.75
Price To Sales (TTM)
4.38
Price To Book (MRQ)
3.26
Price To Cash Flow (TTM)
15.76
Total Debt To Equity (MRQ)
96.77
LT Debt To Equity (MRQ)
76.29
Return on Investment (TTM)
6.05
Return on Equity (TTM)
4.81

Latest News

Latest News

UPDATE 11-UK approves Pfizer-BioNTech COVID-19 vaccine in world first

* EU watchdog urges longer approval process (Adds stock market detail)

UPDATE 4-EU criticises 'hasty' UK approval of COVID-19 vaccine

* UK is first in Western world to authorise a COVID-19 vaccine

UPDATE 1-Brexit Britain just approved a European vaccine, German health minister says

Celebrating Britain's swift approval of BioNtech and Pfizer's coronavirus vaccine as a benefit of Brexit is misplaced since the vaccine was itself a product of the European Union that Britain has left, German Health Minister Jens Spahn said.

CANADA FX DEBT-Canadian dollar holds near 2-year high amid vaccine hopes

* Canadian dollar dips 0.1% against the greenback * The loonie touches its strongest since October 2018 at 1.2916 * Canadian labor productivity falls by a record 10.3% * Canada's 10-year yield touches a near 3-week high at 0.780% TORONTO, Dec 2 (Reuters) - The Canadian dollar...

EXPLAINER-When and how will COVID-19 vaccines become available?

Britain on Wednesday became the first Western country to approve a COVID-19 vaccine, jumping ahead of the United States and Europe after its regulator cleared a shot developed by Pfizer and BioNTech for emergency use in record time.

As U.S. races toward COVID-19 vaccine, Britain takes the lead

Britain leapt ahead of the United States in approving Pfizer's COVID-19 vaccine on Wednesday, intensifying scrutiny on U.S. regulators as they consider whether to grant emergency use in the country that leads the world in coronavirus infections.

Germany says it chose longer approval process of COVID vaccines than UK to boost trust

Germany has opted for a longer procedure to approve COVID-19 vaccines than the emergency process chosen by Britain for the shot developed by Pfizer and BioNTech, because it wanted to increase confidence in vaccines, the country's health minister said on Wednesday.

UK approval of COVID-19 vaccine won’t affect Germany’s doses - ministry

Britain’s approval of Pfizer’s COVID-19 vaccine will not have an impact on the number of doses available in Germany, a spokesman for the German health ministry said on Wednesday.

INSTANT VIEW-Britain approves Pfizer's COVID-19 vaccine, rollout to begin next week

Britain on Wednesday became the first country in the world to approve the COVID-19 vaccine developed by U.S. drugmaker Pfizer and its German partner BioNTech , and said it will be rolled out from early next week.

FACTBOX-With COVID-19 vaccine trial results in, how will Europe deploy the shots?

The frontrunners in the COVID-19 vaccine race have emerged with different success rates for their shots in clinical trials, prompting a scramble across Europe to prepare for the daunting challenge of inoculating 450 million people across almost 30 countries. That race has...

EXPLAINER-When and how will COVID-19 vaccines become available?

Britain on Wednesday became the first Western country to approve a COVID-19 vaccine, jumping ahead of the United States and Europe after its regulator cleared a shot developed by Pfizer and BioNTech for emergency use in record time.

FACTBOX-Pfizer-BioNTech vaccine days away from UK roll-out

* For a separate FACTBOX on other vaccines, click , and click for the frontrunners (Adds UK approval, updates regulatory reviews section) Dec 2 (Reuters) - Britain on Wednesday became the first country in the world to approve the Pfizer-BioNTech COVID-19 vaccine for use...

GLOBAL MARKETS-Stocks rest after vaccine progress, dollar stuck at 2-1/2 year low

World stocks hovered near record highs on Wednesday on hopes for a coronavirus vaccine and additional U.S. economic stimulus, though enthusiasm for riskier assets left the dollar stuck at a 2-1/2 year low.

EU lawmaker warns of risks from UK "hasty" approval of Pfizer COVID vaccine

Britain's emergency approval of the experimental COVID-19 vaccine being developed by Pfizer and BioNTech is "problematic" as it was done too hastily, a prominent European Union lawmaker said on Wednesday.

London stocks subdued as Brexit fears offset first vaccine approval

London-listed shares were muted on Wednesday as fears about a no-deal Brexit overshadowed news that the UK had become the world's first country to approve the Pfizer-BioNTech COVID-19 vaccine.

European shares dip; UK vaccine approval limits losses on FTSE 100

European shares slipped on Wednesday as investors took stock following a near 14% rally last month, while shares in BioNTech surged after UK became the first country to approve its COVID-19 vaccine developed with Pfizer.

US STOCKS-S&P 500, Nasdaq end at record highs on vaccine optimism

* Pfizer-BioNTech seek EU emergency approval for COVID-19 vaccine

US STOCKS-S&P 500, Nasdaq end at record highs on vaccine optimism

* Pfizer-BioNTech seek EU emergency approval for COVID-19 vaccine

US STOCKS-S&P 500, Nasdaq hit records on vaccine optimism

* Pfizer-BioNTech seek EU emergency approval for COVID-19 vaccine

US STOCKS-S&P 500, Nasdaq start December at peak on vaccine optimism

* Pfizer-BioNTech seek EU emergency approval for COVID-19 vaccine

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up